ARTICLE | Clinical News

Berlin Cures' heart failure candidate well tolerated in Phase I

March 16, 2018 4:33 PM UTC

Berlin Cures Holding AG (Zug, Switzerland) reported data from a Phase I trial in 68 healthy volunteers showing that a single IV infusion of heart failure candidate BC007 was well tolerated and eliminated autoantibodies against adrenergic receptor beta 1 (ADRB1). Data were presented at the American College of Cardiology meeting in Orlando.

The primary endpoints of the placebo-controlled, German trial are safety and the conversion rate from positive GPCR autoantibodies to negative immune status. Pharmacokinetics is a secondary endpoint...

BCIQ Company Profiles

Berlin Cures Holding AG

BCIQ Target Profiles

Adrenergic receptor beta 1